Overview of the ChILD Research Network: A roadmap for progress and success in defining rare diseases

Alicia M Casey1, Robin R Deterding2, Lisa R Young3

  • 1Division of Pulmonary Medicine, Harvard Medical School and Boston Children's Hospital, Boston, Massachusetts.

Pediatric Pulmonology
|June 14, 2020
PubMed

Insights

Children's interstitial and diffuse lung diseases are rare, serious lung conditions in kids. Research networks are improving understanding and treatment for these challenging pediatric lung disorders.

Area of Science:

  • Pediatric Pulmonology
  • Rare Diseases
  • Interstitial Lung Disease

Background:

  • Children's interstitial and diffuse lung diseases (ChILD) are rare, serious lung conditions in children.
  • These diseases present with diffuse pulmonary infiltrates and respiratory symptoms, leading to high morbidity and mortality.
  • Limited understanding of natural history and directed therapies pose significant challenges for clinicians.

Purpose of the Study:

  • To review the progress in the field of pediatric interstitial and diffuse lung diseases.
  • To highlight successes achieved through collaborative research efforts.
  • To provide an overview of past and current advancements in ChILD.

Main Methods:

  • Literature review of research on Children's Interstitial and Diffuse Lung Disease.
  • Analysis of successes from the Children's Interstitial Lung Disease Foundation Research Network and Foundation.
  • Synthesis of current knowledge and future directions in ChILD research.

Main Results:

  • Establishment of collaborative networks has driven significant progress in ChILD research.
  • Increased understanding of the complexities of these rare pediatric lung diseases.
  • Development of a growing body of knowledge in this rapidly evolving field.

Conclusions:

  • Collaborative research networks are crucial for advancing ChILD understanding and care.
  • Continued research is essential to address the unmet needs in pediatric interstitial lung diseases.
  • The field of ChILD has seen notable successes, with ongoing potential for further breakthroughs.

Related Concept Videos

Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.6K
Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.7K
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.4K
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
164
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
9.8K
Sex-linked Disorders01:43

Sex-linked Disorders

Like autosomes, sex chromosomes contain a variety of genes necessary for normal body function. When a mutation in one of these genes results in biological deficits, the disorder is considered sex-linked.
107.5K